
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials
PIFELTRO®▼ Prescribing information GB / NI
DELSTRIGO®▼ Prescribing information GB / NI[External links]
DELSTRIGO®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PIFELTRO®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Doravirine/3TC/TDF = DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate)
The proportion of participants with HIV-1 RNA <50 copies/ml at Week 48 in the immediate switch group compared to Week 24 in the delayed switch group.1
Findings: Modest weight gain after more than 2 years on doravirine/3TC/TDF which would be no higher than that expected in an otherwise healthy population.2
Adapted from Kumar P et al. 20212
†Adjusted for weight at time of switch, race (Black/non-Black), ethnicity (Hispanic/other), sex, age, prior therapy class, baseline CD4+ T-cell count, and baseline HIV-1 RNA
§Delayed Switch Group switched to doravirine/3TC/TDF at week 24
Adapted from Kumar P et al. 20212
Immediate Switch Group
Delayed Switch Group
From time of switch to Week 1442
~70% gained less than 5%,
~20% gained 5-10%, and
~8% gained 10% or more
Adapted from Orkin et al. 20203
PIFELTRO®▼ Prescribing information GB / NI
DELSTRIGO®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
PIFELTRO®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
GB-DOR-00204 | Date of Preparation: September 2021